Periocular Manifestations of Afatinib Therapy
Varajini Joganathan1, Jonathan H Norris
1Oxford University Hospital, Headley Way, Headington, Oxford, United Kingdom.
Abstract:
Epidermal growth factor receptor tyrosine kinase inhibitor therapy has been increasingly employed in the treatment of a variety of tumors. The authors report the rarely documented side effect of trichiasis with the use of Afatinib in a patient with spinal chordoma and review-related literature. A 67-year-old lady was referred to the oculoplastic service with a 3-month history of ocular irritation and pain associated with blurred vision. She has a 4-year history of spinal chordoma treated with daily Afatinib 50 mg over the past 6 months. Clinical examination revealed trichomegaly and trichiasis affecting all 4 eyelids associated with blepharitis, conjunctival, and corneal abrasion on fluorescein staining. Hypertrichosis of the eyebrow bilaterally was also present. Afatinib and other epidermal growth factor receptor tyrosine kinase inhibitor-associated changes to eyelash and eyebrow hair is a result of epidermal growth factor receptor pathway activation in keratinocytes results in remodeling of the hair follicle. This results in the variation in the severity of clinical presentation of trichiasis.
Insights
Afatinib, an epidermal growth factor receptor tyrosine kinase inhibitor, can cause trichiasis, an eyelid condition. This rare side effect, observed in a spinal chordoma patient, highlights potential ocular complications of this cancer therapy.
Area of Science:
- Oncology
- Ophthalmology
- Dermatology
Background:
- Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are utilized for various cancers.
- Afatinib is an EGFR-TKI used in cancer treatment.
Observation:
- A 67-year-old female patient with spinal chordoma developed ocular symptoms after 6 months of Afatinib therapy.
- Examination revealed trichomegaly, trichiasis, blepharitis, and corneal abrasion in all four eyelids, along with bilateral eyebrow hypertrichosis.
Findings:
- Afatinib treatment was associated with the rare side effect of trichiasis and other ocular changes.
- EGFR-TKI-induced hair changes result from epidermal growth factor receptor pathway activation in keratinocytes, leading to hair follicle remodeling.
Implications:
- Clinicians should be aware of potential ocular side effects like trichiasis with Afatinib use.
- Understanding the mechanism of EGFR-TKI-induced hair changes can help manage patient symptoms and treatment adherence.
Related Concept Videos
Gene Therapy
Acute Pancreatitis II: Clinical Manifestations and Management
Angina III: Clinical Manifestations and Assessment
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Chronic Kidney Disease II: Clinical Manifestations


